Cernos Gel
Formulated to alleviate symptoms of low testosterone to support muscle density and target localised hormone balance.
- Category
- Hormone Therapy
- Active ingredient
- Testosterone
- Route
- Transdermal use
- Form
- Gel
- Strengths
- 1% 5gm
Prescription and consultation requirements for Cernos Gel vary by destination and are determined by the fulfilment partner.
Cernos Gel details
- Condition
- Male Hypogonadism
- Alternative names
- testosterone
- Therapeutic class
- Androgen
- Pharmacological class
- Testosterone replacement
- Contraindications
- breast cancer in males; known or suspected prostate cancer; pregnancy
- Minor side effects
- acne; local skin irritation
- Moderate side effects
- prostate-specific antigen elevation; increased haematocrit; headache
- Dosage forms
- Gel
- Administration route
- Transdermal use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Sun Pharmaceutical Industries Ltd
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Insulin; Oral Anticoagulants
- Age restrictions
- Approved for adult males.
Serious side effects
deep vein thrombosis, requires immediate medical attention; prostatic hyperplasia progression, requires immediate medical attention
Patient summary
formulated to alleviate symptoms of low testosterone to support muscle density and target localised hormone balance.
Mechanism of action
Provides continuous physiological levels of testosterone, regulating cellular DNA transcription to restore male reproductive characteristics.
Pregnancy and breastfeeding
TGA Category X: Highly contraindicated. Can cause severe virilisation of female fetuses. Breastfeeding: Not applicable.